Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 19, 2024

Identifying Risk to Enable Early Detection of Type 1 Diabetes

An expert reviews risk factors for type 1 diabetes including autoimmune disease and family history, along with the role of autoimmune antibody screening to enable early disease detection, though access to these specialized tests can be limited.

Episodes in this series

Video 1 - "Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2"

EP. 1 Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2

Video 2 - "Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3"

EP. 2 Early-stage Type 1 Diabetes and The Psychological Impact of Progressing to Stage 3

Video 3 - "Identifying Risk to Enable Early Detection of Type 1 Diabetes "

EP. 3 Identifying Risk to Enable Early Detection of Type 1 Diabetes

Video 4 - "Challenges in Autoantibody Screening for Type 1 Diabetes"

EP. 4 Challenges in Autoantibody Screening for Type 1 Diabetes

Video 5 - "Strategies for Preventing Progression of Early-Stage Type 1 Diabetes"

EP. 5 Strategies for Preventing Progression of Early-Stage Type 1 Diabetes

Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"

EP. 6 Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus

Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"

EP. 7 Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Experts featured in this series.

Provider Shortages and Diagnostic Complexity: The Compounding Challenges of Mental Health Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 15th 2026 | Updated: June 15th 2026

The Structural and Scientific Gaps Still Undermining DME Care: Rahul Khurana, MD

ByLaura Joszt, MA,Rahul Khurana, MD

June 15th 2026

The Diagnostic Journey in Extrapulmonary Neuroendocrine Carcinoma: Team-Based Care and Classification

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 15th 2026

The Future of Factor XIa Inhibition: Clinical Integration and Treatment Algorithms

ByMark Makhinson, PharmD, MBA,Andrew Russman, DO, FAHA, FAAN,Danison Emmerson, MD,David Z. Rose, MD

June 15th 2026

Understanding Neuroendocrine Carcinomas: Definitions, Types, and Clinical Presentation

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 15th 2026

Trending on AJMC

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD

SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD